A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

Part of paid clinical trials in Lemon Grove, California.

Sponsor
MapLight Therapeutics
Study ID
NCT07459647
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • ML-007C-MA — DRUG
    ML-007C-MA dosed as 210/3 mg BID

Study Details

ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).

Key Dates

Start date
Mar 31, 2026
Status verified
Mar 2026
Primary completion
Feb 28, 2030
Completion
Feb 28, 2030

Study Design

Enrollment
500 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: ML-007C-MA

Primary Outcome Measure

To assess the safety and tolerability of long-term ML-007C-MA administration in adult participants with schizophrenia [ Time Frame: From initial dose through end of treatment (up to 52 weeks) ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
Clinical SiteLemon GroveCalifornia91945-
Clinical SiteMiami LakesFlorida33016-
Clinical SiteChicagoIllinois60640-
Clinical SiteStaten IslandNew York10314-
Clinical SiteDeSotoTexas75115-

Find similar trials in Lemon Grove, CA

By condition
Schizophrenia
By specialty
PsychiatryMental healthBehavioral health
By research site
Clinical Site· Lemon Grove, CAClinical Site· Miami Lakes, FLClinical Site· Chicago, ILClinical Site· Staten Island, NYClinical Site· DeSoto, TX

Related Studies